Posted by Michael Wonder on 13 Jan 2025
FDA grants fast track designation to Spinogenix's SPG601 for treatment of Fragile X syndrome, a common inherited form of autism
13 January 2025 - -- Spinogenix today announced that the US FDA has granted fast track designation to SPG601 for the treatment of people with Fragile X syndrome.
In 2024, the FDA granted orphan drug designation to SPG601 for the treatment of Fragile X syndrome.
